NY-ESO-1 Based Immunotherapy of Cancer: Current PerspectivesRemy Thomas, Julie Decock|Frontiers in Immunology|2018Cited by 400
PRAME promotes epithelial-to-mesenchymal transition in triple negative breast cancerGhaneya Al‐Khadairi, Julie Decock|Journal of Translational Medicine|2019Cited by 66
Cancer testis antigen PRAME: An anti‐cancer target with immunomodulatory potentialAdviti Naik, Julie Decock|Journal of Cellular and Molecular Medicine|2021Cited by 34
Identification of two HLA-A*0201 immunogenic epitopes of lactate dehydrogenase C (LDHC): potential novel targets for cancer immunotherapyRemy Thomas, Julie Decock|Cancer Immunology Immunotherapy|2020Cited by 31
Cancer testis antigens: Emerging therapeutic targets leveraging genomic instability in cancerAdviti Naik, Julie Decock|Molecular Therapy Oncology|2024Cited by 19